Clinical Trials Sponsored by Kyowa Hakko Kirin Company, Limited

Total 39 results

Kyowa Hakko Kirin Pharma, Inc.

Terminated

Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)

Acute Myelogenous Leukemia (AML)

United States
Kyowa Hakko Kirin Pharma, Inc.

Terminated

Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer

Colorectal Cancer

United States
Kyowa Hakko Kirin Pharma, Inc.

Terminated

Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

Breast Cancer

United States
Kyowa Hakko Kirin Pharma, Inc.

Completed

A Study of KRN23 in X-linked Hypophosphatemia

X-linked Hypophosphatemia

United States
Kyowa Hakko Kirin Pharma, Inc.

Terminated

Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

Neoplasms | Ovarian Neoplasms | Fallopian Tube Neoplasms | Primary Peritoneal Neoplasm

United States
Kyowa Hakko Kirin Pharma, Inc.

Completed

Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor

Solid Tumor

United States
Kyowa Hakko Kirin UK, Ltd.

Completed

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease

Parkinson's Disease

United Kingdom
Kyowa Hakko Kirin Pharma, Inc.

Terminated

Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

Multiple Myeloma

United States
Kyowa Hakko Kirin Pharma, Inc.

Completed

Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)

Peripheral T-Cell Lymphoma

France, United Kingdom, Netherlands, Denmark, Italy, Spain
Kyowa Hakko Kirin UK, Ltd.

Completed

A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma

Multiple Myeloma | Chronic Lymphocytic Leukaemia | B-cell Non-Hodgkin's Lymphoma

United Kingdom
Kyowa Hakko Kirin Pharma, Inc.

Completed

Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma

Peripheral T-Cell Lymphoma

United States
Kyowa Hakko Kirin Pharma, Inc.

Completed

Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

Cutaneous T-cell Lymphoma | Peripheral T-cell Lymphoma

United States
Kyowa Hakko Kirin Pharma, Inc.

Completed

A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Belgium, Finland, Netherlands, Serbia, Sweden
Kyowa Kirin, Inc.
Kyowa Hakko Kirin UK, Ltd.

Completed

An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018

Parkinson's Disease

United States
Kyowa Hakko Kirin Pharma, Inc.

Completed

The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.

Parkinson's Disease

United States
Kyowa Hakko Kirin Pharma, Inc.

Completed

Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline

Hepatic Impairment

United States
Kyowa Hakko Kirin UK, Ltd.

Completed

A Study of KW-3357 in Congenital Antithrombin Deficiency

Congenital Antithrombin Deficiency

France, Germany, Italy, Sweden, United Kingdom
Kyowa Hakko Kirin Pharma, Inc.
Kyowa Kirin Co., Ltd.

Completed

An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia

X-linked Hypophosphatemia

United States, Canada
Kyowa Hakko Kirin Pharma, Inc.
Kyowa Kirin Co., Ltd.

Completed

A Study to Evaluate Abuse Potential of Istradefylline

Drug Abuse

United States
Kyowa Hakko Kirin Pharma, Inc.
Kyowa Kirin Co., Ltd.

Completed

A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease (KW-6002)

Idiopathic Parkinson's Disease

United States, Canada, Czechia, Germany, Israel, Italy, Poland, Serbia
Kyowa Hakko Kirin Pharma, Inc.
Kyowa Kirin Co., Ltd.

Completed

A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia

X-linked Hypophosphatemia

United States, Canada
Kyowa Hakko Kirin Pharma, Inc.
Kyowa Kirin Co., Ltd.

Completed

Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Idiopathic Parkinson's Disease

United States, Canada, Czechia, Germany, Israel, Italy, Poland, Serbia
Kyowa Hakko Kirin Pharma, Inc.
Kyowa Kirin Co., Ltd.

Completed

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States, Philippines, United Kingdom
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin China Pharmaceutical Co., LTD.

Completed

Pharmacokinetic Study of KHK7580 in Healthy Adult Volunteers

Healthy Volunteer

China
Kyowa Hakko Kirin Pharma, Inc.
Teva Pharma

Completed

Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors

Adenocarcinoma of the Pancreas | Solid Tumour | Adenocarcinoma of the Colorectal
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin China Pharmaceutical Co., LTD.

Withdrawn

A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

China
Kyowa Hakko Kirin China Pharmaceutical Co., LTD.

Completed

Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT (ACTIVE)

Hyperparathyroidism; Secondary, Renal

China
Kyowa Hakko Kirin China Pharmaceutical Co., LTD.

Completed

Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia

China
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin China Pharmaceutical Co., LTD.; Kyowa Kirin Korea Co., Ltd.

Completed

Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia

Secondary Hyperparathyroidism

China, Hong Kong, Korea, Republic of, Taiwan
Kyowa Hakko Kirin China Pharmaceutical Co., LTD.

Completed

Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia (ITP)

China
Memorial Sloan Kettering Cancer Center
Kyowa Hakko Kirin Pharma, Inc.

Completed

Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

United States
Seoul National University Hospital
Kyowa Hakko Kirin Pharma, Inc.; Jeil-Kirin Pharmaceutical Inc.

Completed

Pharmacokinetic, Pharmacodynamic and Safety Evaluation After Single Oral Administration of KRN1493

Healthy

Korea, Republic of
Royal Surrey County Hospital NHS Foundation Trust
Kyowa Hakko Kirin UK, Ltd.

Completed

Study of Opioid-Induced Constipation 1 Project (StOIC-1)

Cancer | Opioid-induced Constipation | Cancer Pain

United Kingdom
Royal Surrey County Hospital NHS Foundation Trust
Kyowa Hakko Kirin UK, Ltd.

Completed

Study of Opioid-Induced Constipation 2 Project (StOIC-2)

Cancer | Opioid-induced Constipation | Cancer Pain

United Kingdom
H. Lee Moffitt Cancer Center and Research Institute
Kyowa Hakko Kirin Pharma, Inc.

Recruiting

Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT) (PLIGHT)

Mycosis Fungoides

United States
Kirin Holdings Company, Limited
Biofortis Clinical Research, Inc.

Completed

Cognitive Effects of Citicoline on Attention in Healthy Men and Women

Healthy

United States
University of North Texas, Denton, TX
Kirin Holdings Company, Limited

Completed

Effects of Glutathione on Immunity in Individuals Training for a Marathon

Healthy

United States
University of North Carolina, Chapel Hill
Kirin Holdings Company, Limited

Completed

Setria Performance Blend Supplementation

Healthy

United States
Institut de Recherches Internationales Servier
Kyowa Kirin Co., Ltd.; ADIR, a Servier Group company

Completed

A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Japan

Clinical Trials Sponsored by Kyowa Hakko Kirin Company, Limited

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations